We are live on ! Find out more
AZN icon

AstraZeneca

386 hedge funds and large institutions have $6.15B invested in AstraZeneca in 2015 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 126 increasing their positions, 131 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $129M | Put options by funds: $50.2M

0.28% less ownership

Funds ownership: 7.39%7.12% (-0.28%)

4% less repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 131

4% less funds holding

Funds holding: 404386 (-18)

6% less capital invested

Capital invested by funds: $6.57B → $6.15B (-$416M)

25% less first-time investments, than exits

New positions opened: 43 | Existing positions closed: 57

60% less funds holding in top 10

Funds holding in top 10: 104 (-6)

Holders
386
Holders Change
-18
Holders Change %
-4.46%
% of All Funds
10.24%
Holding in Top 10
4
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-60%
% of All Funds
0.11%
New
43
Increased
126
Reduced
131
Closed
57
Calls
$129M
Puts
$50.2M
Net Calls
+$79.2M
Net Calls Change
-$355M

AZN Hedge Fund Activity: Q1 2015 in Review

386 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2015, worth a combined $6.15B — down 6.3% from $6.57B a quarter earlier.

Sellers outnumbered buyers: 57 funds closed out of AZN and 43 opened new positions — a net loss of 14 holders — while 131 trimmed existing stakes and 126 added.

The largest buyer was Capital International Investors, adding an estimated $144M. The largest seller was Arrowstreet Capital, cutting an estimated $307M.

  • 386 institutional investors held AstraZeneca (AZN) as of Q1 2015, down from 404 in Q4 2014.
  • Funds reported $6.15B of AstraZeneca stock for Q1 2015, down 6.3% quarter-over-quarter.
  • 43 funds opened new AstraZeneca positions in Q1 2015 and 57 closed out, a net change of -14 holders.
  • The largest AstraZeneca buyer in Q1 2015 was Capital International Investors, an estimated $144M added.
  • The largest AstraZeneca seller in Q1 2015 was Arrowstreet Capital, an estimated $307M sold.

Based on aggregated 13F filings for Q1 2015.